Many thanks Christoph,

Looking ok from my side. Just wondering whether you do not want to table the (non)patentability of random mutagenesis more explicitly in the agenda, e.g. under or as part of agenda point 1 - definition of EBP.

Best regards,

Bram

From: Npos_2018 <npos_2018-bounces@testbiotech.de> On Behalf Of Christoph Then
Sent: Wednesday, 8 July 2020 10:04
To: npos_2018@testbiotech.de
Subject: [Npos_2018] draft agenda for phone call with EPO

Dear all

as agreed, I drafted some agenda for the phone call on 14 July.

please see below.

I would send this draft (after corrections etc) to EPO tomorrow morning

please let me know your comments

thanks!

Christoph

Dear..

During the meeting with the EPO we would like to focus on for topics and then potentially discuss other issues. These four topics are (as outlinied in our letter):

• definition of essentially biological processes
• patentability of cells
• scope of patents
• effect of G3/19 on pending patent applications

To discuss the issue, we propose the following agenda:

1. Short introduction of participants

2. Short summary of problems remaining or newly emerging after G3/19 from the perspective of No Patents on Seeds!

3. Some comments from the EPO on the problem analysis of No Patents on Seeds!

4. First round of discussion / questions

5. Short summary of possible solutions as proposed by No Patents on Seeds!

6. Some comments from the EPO on the solutions analysis of No Patents on Seeds!

7. Second round of discussion / questions

8. Short summary on the findings

9. Other issues such as transparency and CSO participation in meetings of the Administrative Council

10. Further exchanges of views between No Patents on Seeds and the EPO in near future